MIDATECH PHARMA
News | News Release
May 11, 2016
AGM Statement and Update on Trading

Midatech Pharma (AIM: MTPH; Nasdaq: MTP), today will host its Annual General Meeting at Panmure Gordon & Co, One New Change, London, EC4M 9AF at 9:30am BST. Commenting on the Company’s performance in 2016, Midatech's Chairman, Rolf Stahel, will make the following statement:

“Midatech is pleased with the progress made in all aspects of its business in the first four months of 2016. The key product candidates in our clinical pipeline have each seen favourable results that support further development. Our recently acquired US commercial arm has been successfully integrated within Midatech and its recent product launch of Zuplenz™ continues to make good progress. In the first four months of 2016 we have seen strong revenues from our marketed products and as a result the Group is trading slightly ahead of consensus market expectations.

“Midatech is rapidly assembling the strong foundations for an outstanding specialty pharma company. The Company now has a robust revenue-generating US commercial operation marketing a growing portfolio of oncology supportive care products that complement an exciting high-value, niche product pipeline that leverages Midatech’s proprietary drug delivery platform technology. One such example of a product using Midatech’s nanoparticle drug delivery technology is its drug candidate targeting a rare form of brain cancer called Diffuse Intrinsic Pontine Glioma (DIPG). DIPG has a dismal prognosis where alternatives are few and Midatech, in remarkable time, has been able to supply drug to children via a compassionate use programme for one of the most resistant of all cancers to standard chemotherapy treatments.

"The highly driven management team and the Board of Directors looks forward to building upon this success throughout the course of 2016.”

News
News Release
May 11, 2016
AGM Statement and Update on Trading

Midatech Pharma (AIM: MTPH; Nasdaq: MTP), today will host its Annual General Meeting at Panmure Gordon & Co, One New Change, London, EC4M 9AF at 9:30am BST. Commenting on the Company’s performance in 2016, Midatech's Chairman, Rolf Stahel, will make the following statement:

“Midatech is pleased with the progress made in all aspects of its business in the first four months of 2016. The key product candidates in our clinical pipeline have each seen favourable results that support further development. Our recently acquired US commercial arm has been successfully integrated within Midatech and its recent product launch of Zuplenz™ continues to make good progress. In the first four months of 2016 we have seen strong revenues from our marketed products and as a result the Group is trading slightly ahead of consensus market expectations.

“Midatech is rapidly assembling the strong foundations for an outstanding specialty pharma company. The Company now has a robust revenue-generating US commercial operation marketing a growing portfolio of oncology supportive care products that complement an exciting high-value, niche product pipeline that leverages Midatech’s proprietary drug delivery platform technology. One such example of a product using Midatech’s nanoparticle drug delivery technology is its drug candidate targeting a rare form of brain cancer called Diffuse Intrinsic Pontine Glioma (DIPG). DIPG has a dismal prognosis where alternatives are few and Midatech, in remarkable time, has been able to supply drug to children via a compassionate use programme for one of the most resistant of all cancers to standard chemotherapy treatments.

"The highly driven management team and the Board of Directors looks forward to building upon this success throughout the course of 2016.”

© Copyright 2017 Midatech Pharma PLC